• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Timely Monitoring COVID-19 Vaccine Protection, Berlin, Germany, April 15th to December 15th, 2021.

作者信息

Bitzegeio Julia, Hemmers Lukas, Bartel Alexander, Werber Dirk

机构信息

State Office for Health and Social Affairs, Berlin, Germany.

Department of Infectious Disease Epidemiology, Robert Koch Institute, Berlin, Germany.

出版信息

Int J Public Health. 2022 Mar 21;67:1604633. doi: 10.3389/ijph.2022.1604633. eCollection 2022.

DOI:10.3389/ijph.2022.1604633
PMID:35387147
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8977412/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b150/8977412/a58f067870a5/ijph-67-1604633-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b150/8977412/86018de05f0e/ijph-67-1604633-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b150/8977412/a58f067870a5/ijph-67-1604633-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b150/8977412/86018de05f0e/ijph-67-1604633-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b150/8977412/a58f067870a5/ijph-67-1604633-g002.jpg

相似文献

1
Timely Monitoring COVID-19 Vaccine Protection, Berlin, Germany, April 15th to December 15th, 2021.2021年4月15日至12月15日于德国柏林进行的新冠疫苗保护及时监测
Int J Public Health. 2022 Mar 21;67:1604633. doi: 10.3389/ijph.2022.1604633. eCollection 2022.
2
Effectiveness of BNT162b2 and CoronaVac COVID-19 vaccination against asymptomatic and symptomatic infection of SARS-CoV-2 omicron BA.2 in Hong Kong: a prospective cohort study.BNT162b2 和 CoronaVac 新冠疫苗对奥密克戎 BA.2 亚谱系引起的 SARS-CoV-2 无症状和有症状感染的有效性：一项前瞻性队列研究。
Lancet Infect Dis. 2023 Apr;23(4):421-434. doi: 10.1016/S1473-3099(22)00732-0. Epub 2022 Dec 12.
3
Application of a life table approach to assess duration of BNT162b2 vaccine-derived immunity by age using COVID-19 case surveillance data during the Omicron variant period.应用寿命表方法评估奥密克戎变异期间使用 COVID-19 病例监测数据按年龄划分的 BNT162b2 疫苗衍生免疫的持续时间。
PLoS One. 2023 Sep 20;18(9):e0291678. doi: 10.1371/journal.pone.0291678. eCollection 2023.
4
Effect of mRNA Vaccine Boosters against SARS-CoV-2 Omicron Infection in Qatar.mRNA 疫苗加强剂对卡塔尔奥密克戎感染的保护效果。
N Engl J Med. 2022 May 12;386(19):1804-1816. doi: 10.1056/NEJMoa2200797. Epub 2022 Mar 9.
5
Follow-up SARS-CoV-2 serological study of a health care worker cohort following COVID-19 booster vaccination.新冠病毒加强疫苗接种后医护人员队列的后续严重急性呼吸综合征冠状病毒2血清学研究
BMC Infect Dis. 2024 Apr 24;24(1):436. doi: 10.1186/s12879-024-09338-5.
6
Waning of specific antibodies against Delta and Omicron variants five months after a third dose of BNT162b2 SARS-CoV-2 vaccine in elderly individuals.接种 BNT162b2 疫苗加强针 5 个月后老年人对 Delta 和奥密克戎变异株特异性抗体滴度的下降
Front Immunol. 2022 Nov 14;13:1031852. doi: 10.3389/fimmu.2022.1031852. eCollection 2022.
7
Protection against symptomatic infection with delta (B.1.617.2) and omicron (B.1.1.529) BA.1 and BA.2 SARS-CoV-2 variants after previous infection and vaccination in adolescents in England, August, 2021-March, 2022: a national, observational, test-negative, case-control study.2021 年 8 月至 2022 年 3 月，英国青少年在先前感染和接种疫苗后对 delta（B.1.617.2）和 omicron（B.1.1.529）BA.1 和 BA.2 SARS-CoV-2 变异株的症状性感染的保护作用：一项全国性、观察性、基于检测的病例对照研究。
Lancet Infect Dis. 2023 Apr;23(4):435-444. doi: 10.1016/S1473-3099(22)00729-0. Epub 2022 Nov 24.
8
Effectiveness of mRNA vaccines and waning of protection against SARS-CoV-2 infection and severe covid-19 during predominant circulation of the delta variant in Italy: retrospective cohort study.在意大利德尔塔变异株流行期间，mRNA 疫苗对 SARS-CoV-2 感染和重症 COVID-19 的有效性及其保护作用的衰减：回顾性队列研究。
BMJ. 2022 Feb 10;376:e069052. doi: 10.1136/bmj-2021-069052.
9
Analysis of COVID-19 Incidence and Severity Among Adults Vaccinated With 2-Dose mRNA COVID-19 or Inactivated SARS-CoV-2 Vaccines With and Without Boosters in Singapore.分析新加坡成年人接种 2 剂 mRNA COVID-19 或灭活 SARS-CoV-2 疫苗以及接种加强针后的 COVID-19 发病率和严重程度。
JAMA Netw Open. 2022 Aug 1;5(8):e2228900. doi: 10.1001/jamanetworkopen.2022.28900.
10
Effectiveness of a COVID-19 Additional Primary or Booster Vaccine Dose in Preventing SARS-CoV-2 Infection Among Nursing Home Residents During Widespread Circulation of the Omicron Variant - United States, February 14-March 27, 2022.奥密克戎变异株广泛传播期间，养老院居民接种 COVID-19 追加初级或加强疫苗剂量对预防 SARS-CoV-2 感染的效果-美国，2022 年 2 月 14 日-3 月 27 日。
MMWR Morb Mortal Wkly Rep. 2022 May 6;71(18):633-637. doi: 10.15585/mmwr.mm7118a4.

引用本文的文献

1
Vaccine effectiveness against emerging COVID-19 variants using digital health data.利用数字健康数据评估疫苗对新出现的新冠病毒变体的有效性。
Commun Med (Lond). 2024 May 6;4(1):81. doi: 10.1038/s43856-024-00508-9.

本文引用的文献

1
Durability analysis of the highly effective BNT162b2 vaccine against COVID-19.高效BNT162b2新冠疫苗的耐久性分析
PNAS Nexus. 2022 Jun 8;1(3):pgac082. doi: 10.1093/pnasnexus/pgac082. eCollection 2022 Jul.
2
Waning Immunity after the BNT162b2 Vaccine in Israel.以色列接种 BNT162b2 疫苗后的免疫力下降。
N Engl J Med. 2021 Dec 9;385(24):e85. doi: 10.1056/NEJMoa2114228. Epub 2021 Oct 27.
3
Effectiveness of COVID-19 vaccines against SARS-CoV-2 infection with the Delta (B.1.617.2) variant: second interim results of a living systematic review and meta-analysis, 1 January to 25 August 2021.
COVID-19 疫苗对 Delta（B.1.617.2）变异株感染的有效性：2021 年 1 月 1 日至 8 月 25 日期间一项实时系统评价和荟萃分析的第二次中期结果。
Euro Surveill. 2021 Oct;26(41). doi: 10.2807/1560-7917.ES.2021.26.41.2100920.
4
Effect of Delta variant on viral burden and vaccine effectiveness against new SARS-CoV-2 infections in the UK.德尔塔变异株对英国新冠病毒载量及针对新型严重急性呼吸综合征冠状病毒2感染的疫苗效力的影响。
Nat Med. 2021 Dec;27(12):2127-2135. doi: 10.1038/s41591-021-01548-7. Epub 2021 Oct 14.
5
Waning of BNT162b2 Vaccine Protection against SARS-CoV-2 Infection in Qatar.卡塔尔：BNT162b2 疫苗对 SARS-CoV-2 感染的保护作用逐渐减弱。
N Engl J Med. 2021 Dec 9;385(24):e83. doi: 10.1056/NEJMoa2114114. Epub 2021 Oct 6.
6
Waning Immune Humoral Response to BNT162b2 Covid-19 Vaccine over 6 Months.辉瑞-BioNTech 新冠疫苗接种 6 个月后免疫体液反应逐渐减弱。
N Engl J Med. 2021 Dec 9;385(24):e84. doi: 10.1056/NEJMoa2114583. Epub 2021 Oct 6.
7
Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) Variant.Covid-19 疫苗对 B.1.617.2（德尔塔）变异株的有效性。
N Engl J Med. 2021 Aug 12;385(7):585-594. doi: 10.1056/NEJMoa2108891. Epub 2021 Jul 21.
8
Age-dependent Immune Response to the Biontech/Pfizer BNT162b2 Coronavirus Disease 2019 Vaccination.年龄相关的对辉瑞/生物科技 BNT162b2 冠状病毒病 2019 疫苗接种的免疫反应。
Clin Infect Dis. 2021 Dec 6;73(11):2065-2072. doi: 10.1093/cid/ciab381.
9
[Adaptation of the routine surveillance system for infectious diseases in 2020 in the context of the COVID-19 pandemic].[2020年新冠疫情背景下传染病常规监测系统的适应性调整]
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2021 Apr;64(4):388-394. doi: 10.1007/s00103-021-03298-w. Epub 2021 Apr 13.